BioXmark®液体基准标记物用于直肠癌放疗肿瘤加量的可行性试验
这项前瞻性、非随机、单臂可行性试验纳入20例接受新辅助放化疗的局部晚期直肠癌患者,评估新型液体基准标记物(BioXmark®)在放疗期间的位置稳定性、技术可行性、不同影像模态下的可见性及安全性。主要终点为每日锥形束CT上的位置稳定性,74枚标记物中96%保持稳定,CT和锥形束CT可见性良好,MRI应答评估时可见性差。
要点
- 74枚标记物中96%在CBCT上位置稳定,1枚临床相关迁移、1枚治疗前丢失、1枚治疗中丢失。
- 标记物在CT和CBCT上可见性良好,EPI上中等,MRI应答评估时可见性差。
- 该液体基准标记物用于直肠癌每日CBCT图像引导放疗具可行性。
核心结论
- 新型液体基准标记物表现出位置稳定性,为直肠癌患者每日锥形束CT图像引导放疗的可行性提供了证据。
研究设计与样本
- 前瞻性、非随机、单臂可行性试验,纳入20例转诊接受新辅助放化疗的局部晚期直肠癌患者。
- 主要研究终点为锥形束CT上的位置稳定性,同时评估技术方面、安全性及标记物在不同影像模态下的可见性等临床性能。
主要发现
- 20例患者的74枚标记物可进行分析。
- 标记物在96%的病例中保持稳定。
- 1枚标记物显示临床相关迁移,1枚标记物在治疗开始前丢失,1枚标记物在治疗期间丢失。
- 标记物在计算机断层扫描(CT)和锥形束CT上可见性良好,在电子射野影像(EPI)上可见性中等。
- 标记物在磁共振成像(MRI)应答评估时可见性差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Dose-escalation in rectal cancer (RCa) may result in an increased complete response rate and thereby enable omission of surgery and organ preservation. In order to implement dose-escalation, it is crucial to develop a technique that allows for accurate image-guided radiotherapy. The aim of the current study was to determine the performance of a novel liquid fiducial marker (BioXmark®) in RCa patients during the radiotherapy course by assessing its positional stability on daily cone-beam CT (CBCT), technical feasibility, visibility on different imaging modalities and safety. MATERIALS AND METHODS: Prospective, non-randomized, single-arm feasibility trial with inclusion of twenty patients referred for neoadjuvant chemoradiotherapy for locally advanced RCa. Primary study endpoint was positional stability on CBCT. Furthermore, technical aspects, safety and clinical performance of the marker, such as visibility on different imaging modalities, were evaluated. RESULTS: Seventy-four markers from twenty patients were available for analysis. The marker was stable in 96% of the cases. One marker showed clinically relevant migration, one marker was lost before start of treatment and one marker was lost during treatment. Marker visibility was good on computed tomography (CT) and CBCT, and moderate on electronic portal imaging (EPI). Marker visibility on magnetic resonance imaging (MRI) was poor during response evaluation. CONCLUSION: The novel liquid fiducial marker demonstrated positional stability. We provide evidence of the feasibility of the novel fiducial marker for image-guided radiotherapy on daily cone beam CT for RCa patients.
引用
- Opbroek TJS, Willems YCP, Verhaegen F, et al. BioXmark® liquid fiducials to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial. Clin Transl Radiat Oncol. 2022. PMID: 36407490. doi:10.1016/j.ctro.2022.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。